Engineered tRNA offers a potential new route for treating genetic disease

Researchers at the University of Toronto reported an engineered transfer RNA (tRNA) therapy that could address genetic diseases caused by premature stop-codon mutations.

In laboratory and preclinical cystic-fibrosis models, inhaled modified tRNA enabled cells to read through the premature stop signal and produce full-length, functional CFTR protein.

In mice, the treatment reached the lungs, appeared safe, and persisted in relevant epithelial cells for up to 40 days. It also restored mutated protein function and could potentially be combined with existing cystic-fibrosis medicines.

Unlike mRNA replacement, tRNA does not encode a new therapeutic protein. It helps the cell’s existing mRNA get translated past the faulty stop signal, potentially allowing one tRNA design to treat related mutations across multiple genes and diseases.

The approach remains experimental. Researchers still need to establish long-term safety, delivery, immune effects, dosage, and effectiveness in humans.

The report appeared in Science on August 27, 2026, according to the available coverage.